Pharmacokinetic Aspects of Controlled Drug Delivery Systems

  • Gerhard Levy
Part of the ALZA Conference Series book series (ALZA, volume 2)


It is now possible, in principle, to develop drug delivery systems which release medicinal agents at selected sites in the body at selected constant rates and even at variable rates according to a particular temporal pattern. This capability affords a degree of control which far exceeds that of conventional modes of drug administration. It is timely, therefore, to consider some of the potential advantages of such controlled drug delivery systems, the pharmacokinetic and physiologic principles upon which their release pattern must be based, and the basic information required to design delivery systems for a specific drug and a particular therapeutic or prophylactic purpose.


Drug Concentration Pharmacologic Effect Central Compartment Drug Elimination Peripheral Compartment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aghajanian, G.K., and Bing, O.H.L., 1964. Persistence of lysergic acid diethylamide in the plasma of human subjects, Clin. Pharmacol. & Therap. 5:611–614.Google Scholar
  2. 2.
    Dettli, L., and Spring, P., 1966. Diurnal variations in the elimination rate of a sulfonamide in man, Helvetica Medica Acta 33:291–306.Google Scholar
  3. 3.
    DiSanto, A.R., and Wagner, J.G., 1972. Pharmacokinetics of highly ionized drugs II: Methylene blue — absorption, metabolism, and excretion in man and dog after oral administration, J. Pharm. Sci. 61:1086–1090.CrossRefGoogle Scholar
  4. 4.
    Doherty, J.E., 1971. Digitalis serum levels: clinical use, Ann. Intern. Med. 74:787–789.Google Scholar
  5. 5.
    Drucker, M.M., Blondheim, S.H., and Wislicki, L., 1964. Factors affecting acetylation in vivo of para-aminobenzoic acid by human subjects, Clin. Sci. 27:133–141.Google Scholar
  6. 6.
    Gibaldi, M., Levy, G., and Weintraub, H., 1971. Drug distribution and pharmacologie effects, Clin. Pharmacol. & Therap. 12:734–742.Google Scholar
  7. 7.
    Gibaldi, M., Levy, G., and Hayton, W.L., 1972a. Kinetics of the elimination and neuromuscular blocking effect of d-tubocurarine in man, Anesthesiology 36:213–218.CrossRefGoogle Scholar
  8. 8.
    Gibaldi, M., Levy, G., and Hayton, W.L., 1972b. Tubocurarine and renal failure, Brit. J. Anaesth. 44:163–165.CrossRefGoogle Scholar
  9. 9.
    Jenne, J.W., Wyze, E,, Rood, F.S., and MacDonald, F.M., 1972. Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline, Clin. Pharmacol. & Therap. 13:349–360.Google Scholar
  10. 10.
    Koch-Weser, J., 1972. Drug therapy: serum drug concentrations as therapeutic guides, N. Eng. J. Med. 287:227–230.CrossRefGoogle Scholar
  11. 11.
    Kutt, H., and McDowell, F., 1968. Management of epilepsy with diphenylhydantoin sodium, J. Amer. Med. Assoc. 203:969–974.CrossRefGoogle Scholar
  12. 12.
    Leonards, J.R., and Levy, G., 1970. Aspirin-induced occult gastrointestinal blood loss: local versus systemic effects, J. Pharm. Sci. 59:1511–1513.CrossRefGoogle Scholar
  13. 13.
    Levy, G., 1966. Kinetics of pharmacologie effects, Clin. Pharmacol. & Therap. 7:362–372.Google Scholar
  14. 14.
    Levy, G., 1967a. Effect of bed rest on distribution and elimination of drugs, J. Pharm. Sci. 56:928–929.CrossRefGoogle Scholar
  15. 15.
    Levi, G., 1967b. Kinetics of pharmacologic activity of succinylcholine in man, J. Pharm. Sci. 56:1687–1688.CrossRefGoogle Scholar
  16. 16.
    Levy, G., 1969. In Importance of Fundamental Principles in Drug Evaluation (D.H. Tedeschi, and R.E. Tedeschi, eds.), pp. 141–172, Raven Press, New York.Google Scholar
  17. 17.
    Levy, G., 1970. In Prescription Pharmacy (J.B. Sprowls, Jr., ed.), pp. 36–102, Lippincott, Philadelphia, Pa.Google Scholar
  18. 18.
    Levy, G., Ashley, J.J., Jahnchen, E., and Perrier, D., 1972. Hydroxylated metabolites as inhibitors of drug biotransformation and their possible role in dose dependent elimination kinetics, A.Ph.A. Acad. Pharm. Sci. Sym. Abstr.Google Scholar
  19. 19.
    Levy, G., Gibaldi, M., and Jusko, W.J., 1969. Multicompartment pharmacokinetic models and pharmacologic effects, J. Pharm. Sci. 58:422–424.CrossRefGoogle Scholar
  20. 20.
    Levy, G., O’Reilly, R.A., Aggeler, P.M., and Keech, G.M., 1970. Pharmacokinetic analysis of the effect of barbiturate on the anticoagulant action of warfarin in man, Clin. Pharmacol. & Therap. 11:372–377.Google Scholar
  21. 21.
    Murphy, J., Casey, W., and Lasagna, L., 1961. The effect of dosage regimen on the diuretic efficacy of chlorothiazide in human subjects. J.P.E.T., 134:286–290.Google Scholar
  22. 22.
    Nagashima, R., O’Reilly, R.A., and Levy, G., 1969. Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin, Clin. Pharmacol. & Therap. 10:22–35.Google Scholar
  23. 23.
    O’Reilly, R.A., 1970. The second reported kindred with hereditary resistance to oral anticoagulant drugs, N. Eng. J. Med. 282:1448–1451.CrossRefGoogle Scholar
  24. 24.
    O’Reilly, R.A., and Levy, G., 1970. Kinetics of the anticoagulant effect of bishydroxycoumarin in man, Clin. Pharmacol. & Therap. 11:378–384.Google Scholar
  25. 25.
    Tsuchiya, T., and Levy, G., 1972. Relationship between dose and plateau levels of drugs eliminated by parallel first-order and capacity-limited kinetics, J. Pharm. Sci. 61:541–544.CrossRefGoogle Scholar
  26. 26.
    Venter, J.C., Dixon, J.E., Maroko, P.R., and Kaplan, N.O., 1972. Biologically active catecholamines covalently bound to glass beads, Proc. Nat. Acad. Sci. 69:1141–1145.CrossRefGoogle Scholar
  27. 27.
    Vesell, E.S., and Passananti, G.T., 1971. Utility of clinical chemical determinations of drug concentrations in biological fluids, Clin. Chem. 17:851–866.Google Scholar
  28. 28.
    Wagner, J.G., 1968. Kinetics of pharmacologic response I. Proposed relationships between response and drug concentration in the intact animal and man, J. Theoret. Biol. 20:173–201.CrossRefGoogle Scholar
  29. 29.
    Walts, L.F., and Dillon, J.B., 1968. Durations of action of d-tubocurarine and gallamine. Anesthesiology 29:499–504.CrossRefGoogle Scholar
  30. 30.
    Zaffaroni, A., 1972. President’s Letter, ALZA Annual Report.Google Scholar

Copyright information

© Plenum Press, New York 1973

Authors and Affiliations

  • Gerhard Levy
    • 1
  1. 1.Department of Pharmaceutics, School of PharmacyState University of New YorkBuffaloUSA

Personalised recommendations